-
#ACR2019#acr19 new Guidelines OA:
exercise (aerobic/streng/neuroM/aquatic
)


weigth

tai chi
TENS
(no evidence)
topical/oral NDSAIDs/intraarticular GCs
intraarticular HyA (hip)
glucosamine and/or chondroitin
(Look slides 
) pic.twitter.com/Y76IECqkPJ
-
#tbt#ACR19 "Update in Myositis" session with tips on how to use the new classification criteria I honestly find them difficult and only reference in marginal cases Excellent tables from the presentation, though - great reference for antibodies and presentations!@RheumNowpic.twitter.com/SyzhLZHtcI
-
Rt
@ACRheum: Episode 7 of ACR on Air looks at a few more studies featured during our#ACR19 press conferences. Listen at: https://acr.tw/32Na5F8 pic.twitter.com/x41hbnzuA6
-
¿Conoces nuestros highlights del encuentro anual del American College of Rheumatology que se celebró en Atlanta? Visiona estos vídeos con el Dr. Jesús Tornero, Servicio de
#Reumatología Hospital de Guadalajara#IL6#ArtritisReumatoide#ACR19#ACR2019
https://www.artritis-il6.es/atlanta-2019-1 pic.twitter.com/AEB1JV6NVj
-
Check our podcast on one of the highlights from
#ACR19: results of next promising new treatments in#psoriaticarthritis &#spondyloarthritis with@Stiddyo & Dr Atul Deodharhttps://soundcloud.com/bmjpodcasts/acr-paul-studenic-and-atul-deodha?in=bmjpodcasts/sets/ard-podcast … -
Retrospective cohort study of 154 RA patients undergoing 244 major surgeries in shows that perioperative use of DMARDs (39%) or biologics (13%) was not associated with 30-day odds of post-operative infection
#ACR19 Abst #1805 http://bit.ly/34rmyie -
It’s a good day (& year!) for
#lupus#nephritis#patients - 1st we had positive#Nobility phase2 trial#obinutuzumab (@Roche) reported@ASNKidney#KidneyWk &#ACR19. & today, phase3#Voclosporin hits primary & secondary endpoints in#AURORA@AuriniaPharmahttps://ir.auriniapharma.com/press-releases/detail/164/aurinia-announces-positive-aurora-phase-3-trial-results …Prikaži ovu nit -
Management of GCA Guidelines from
#ACR19 (FIXED!): The presenter went quickly by the slide on methotrexate & the slide deck was not available during the presentation. Small update now that slides are available, MTX recs included: "[MTX] can be considered as initial treatment" pic.twitter.com/Cm7jBPeGZz
-
This is the best summary of
#ACR19 that I’ve seen. Great work putting this together@laurenbgelman and the rest of the@CreakyJoints community.@SethSaidSohttps://twitter.com/laurenbgelman/status/1198779600802844672 … -
Excited to share this
@CreakyJoints report of the big#ACR19 takeaways for patients, with lots of help from@rheum_cat@psufka@EBRheum@HealioRheum@RheumNow & others. Too much to pack into just one resource, so we have 6 wrap-up stories this year!https://creakyjoints.org/education/acr-2019-research/ … -
I missed this one during
#ACR19 (found via@RheumNow's weekly roundup): Abstract L19: Early study, but BAFF inhibitor Ianalumab met its primary endpoint in primary Sjogren's.https://acrabstracts.org/abstract/ianalumab-vay736-a-dual-mode-of-action-biologic-combining-baff-receptor-inhibition-with-b-cell-depletion-for-treatment-of-primary-sjogrens-syndrome-results-of-an-international-randomized/ … -
#tbt#ACR19 - Update in Myositis: Don't forget about toxin induced myopathy! Important mimickers related to treatment we give! 1. Steroid: myopathy w/o inflammation 2. Colchicine: vacuolar myopathy 3. Anti-malarial: vacuolar degeneration P.S. This might be good boards prep... pic.twitter.com/m48UkZlGP3
-
spent several days in atlanta w/ my friends & colleagues
@Xtel007 &@SynceNerd_Carli. it’s taken many years of advocacy to reach this moment. thank you@acrheum for inviting patient advocates in such a meaningful way to author abstracts & present posters at#ACR19 #LupusChatpic.twitter.com/APQMT3YkZx
-
I wrote about being a first time patient at
@ACRheum#ACR19 . What an amazing experience, I WILL go again! Thank you@Arthritis_ARC for sponsoring me! Thank you@steveston_gal for being my mentor. Also thanks to those who came to see me speak!http://bit.ly/37hHwmD -
Presenting our poster "Antisynthetase Syndromes: Correlation of IIFA Patterns with Diagnosis Criteria Fulfillment" at
#ACR19 in Atlanta. Many thanks to@fmguanarteme,@MdicosLasPalmas and@SEReumatologia for contributing to this project and its presentation at this meeting.pic.twitter.com/jtIa7cApl9
-
The gist:
#Hydroxychloroquine blood levels and thrombotic events in#SLE. Risk reduction may be 2-3 times higher than for aspirin in secondary prevention of vascular events. Need to define treat to target strategies.#ACR19@ACRheum@HealioRheum@RheumNow@HopkinsMedNewspic.twitter.com/J4kaDWKu21
-
Can the happiest subspecialists experience burnout?
Now back from #ACR19, I am rekindled with a new spark and inspiration thanks to each and every one of you!
Please read my article for @RheumNow on burnout in rheumatology: http://bit.ly/32OXCkb -
Are you looking
for a visual summary
of the main #clinicaltrials (and their#targets
& #outcomes) for the#treatment
of systemic #lupus presented at#ACR19?#SLE
Well...here it is!pic.twitter.com/kx1EE3zCXq
-
Nouvelles recos sur la goutte au congrès
#ACR19
Crise: AINS ou colchicine petite dose
Hypouricémiant à introduire au moment de la crise (ça me fait bizarre d'écrire ça)
Pas d'hypouricémiant pour une uricémie haute sans crise
Allopurinol 1ere ligne (pour u<360umol/l) https://twitter.com/EBRheum/status/1194683181481562115 …
-
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.